keyword
MENU ▼
Read by QxMD icon Read
search

Cancer of prostate biomarkers

keyword
https://www.readbyqxmd.com/read/28102565/development-of-novel-sers-probe-for-selective-screening-of-healthy-prostate-from-malignant-prostate-cancer-cells-using-zn-ii
#1
Paresh Chandra Ray, Avijit Pramanik, Suhash Reddy Chavva, Bhanu Priya Viraka Nellore, Kelli May, Tejus Matthew, Stacy Jones, Aruna Vangara
Even in 21st century, prostate cancer remains the second leading cause of cancer death for men. Since normal prostate gland contains the most Zn(II) and there are huge differences in Zn(II) content between the healthy and malignant prostate cancer cells, mobile zinc can be used as a biomarker for prostate cancer prediction. Current article reports the design of novel and highly efficient surface enhanced Raman spectroscopy (SERS) probe using p-(imidazole)azo) benzenethiol attached gold nanoparticle as a Raman reporter, which has the capability to identify prostate cancer cells based on Zn(II) sensing...
January 19, 2017: Chemistry, An Asian Journal
https://www.readbyqxmd.com/read/28096201/serum-c-peptide-total-and-high-molecular-weight-adiponectin-and-pancreatic-cancer-do-associations-differ-by-smoking
#2
Leticia M Nogueira, Christina C Newton, Michael N Pollak, Debra T Silverman, Demetrius Albanes, Satu Männistö, Stephanie J Weinstein, Eric J Jacobs, Rachael Z Stolzenberg-Solomon
BACKGROUND: Studies examining associations between circulating concentrations of C-peptide and total adiponectin, two biomarkers related to obesity and insulin secretion and sensitivity and pancreatic ductal adenocarcinoma (PDA) risk have shown inconsistent results and included limited numbers of smokers. METHODS: We examined associations of these biomarkers and high molecular weight (HMW) adiponectin with PDA, overall, and by smoking status. We conducted a pooled nested case-control analysis in 3 cohorts (Prostate, Lung, Colorectal, and Ovarian Cancer Trial, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, and Cancer Prevention Study-II), with 758 cases (435 current smokers) and 1052 controls (531 smokers) matched by cohort, age, sex, race, blood draw date and follow-up time...
January 17, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28092730/serum-agr2-as-a-useful-biomarker-for-pituitary-adenomas
#3
Mamatemin Tohti, Junyang Li, Chao Tang, Guodao Wen, Abdukeyum Abdujilil, Parhat Yizim, Chiyuan Ma
OBJECTIVE: This study aims to evaluate whether the serum Anterior Gradient-2 (AGR2) can be used as a potential biomarker screening in the diagnosis of Pituitary adenomas(PAs). PATIENTS AND METHODS: The serum AGR2 protein levels were preoperatively measured in 163 PA patients, 43 patients with other sellar lesions excluding PAs, 7 patients with prostate cancer as a positive control and 20 normal people(10 female and 10 male) using Enzyme-Linked ImmunoSorbent Assay (ELISA)...
January 9, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28092670/neuropilin-1-is-upregulated-in-the-adaptive-response-of-prostate-tumors-to-androgen-targeted-therapies-and-is-prognostic-of-metastatic-progression-and-patient-mortality
#4
B W C Tse, M Volpert, E Ratther, N Stylianou, M Nouri, K McGowan, M L Lehman, S J McPherson, M Roshan-Moniri, M S Butler, J Caradec, C Y Gregory-Evans, J McGovern, R Das, M Takhar, N Erho, M Alshalafa, E Davicioni, E M Schaeffer, R B Jenkins, A E Ross, R J Karnes, R B Den, L Fazli, P A Gregory, M E Gleave, E D Williams, P S Rennie, R Buttyan, J H Gunter, L A Selth, P J Russell, C C Nelson, B G Hollier
Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC)...
January 16, 2017: Oncogene
https://www.readbyqxmd.com/read/28086943/a-lifestyle-intervention-among-elderly-men-on-active-surveillance-for-non-aggressive-prostate-cancer-a-randomised-feasibility-study-with-whole-grain-rye-and-exercise
#5
Anne Kirstine Eriksen, Rikke Dalgaard Hansen, Michael Borre, Ryan Godsk Larsen, Jeppe Munthe Jensen, Kristian Overgaard, Mette Borre, Cecilie Kyrø, Rikard Landberg, Anja Olsen, Anne Tjønneland
BACKGROUND: The prognosis for men with non-aggressive prostate cancer is good, and several studies have investigated the impact of lifestyle changes including physical activity and diet on the prognosis. Despite positive results in animal studies and a few human interventions with whole-grain rye on markers of prostate cancer progression, the feasibility of trials investigating such dietary changes in combination with physical activity remains largely unstudied. The primary aim was to investigate the feasibility of an intervention with high whole-grain rye intake and vigorous physical activity for 6 months in men diagnosed with prostate cancer...
January 13, 2017: Trials
https://www.readbyqxmd.com/read/28077788/androgen-receptor-splice-variants-and-prostate-cancer-from-bench-to-bedside
#6
REVIEW
Kristine M Wadosky, Shahriar Koochekpour
Therapeutic interventions for advanced prostate cancer (PCa) center on inhibiting androgen receptor (AR) and downstream signaling pathways. Resistance to androgen deprivation therapy and/or AR antagonists is inevitable and molecular mechanisms driving castration-resistant PCa (CR-PCa) primarily involve alterations in AR expression and activity. Detailed molecular biology work over the past decade, discussed at length in this review article, has revealed several AR transcripts that result from alternative splicing...
January 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28074002/metabolic-profiling-in-formalin-fixed-and-paraffin-embedded-prostate-cancer-tissues
#7
Stefano Cacciatore, Giorgia Zadra, Clyde Bango, Kathryn L Penney, Svitlana Tyekucheva, Oscar Yanes, Massimo Loda
: Metabolite profiling has significantly contributed to a deeper understanding of the biochemical metabolic networks and pathways in cancer cells. Metabolomics-based biomarker discovery would greatly benefit from the ability to interrogate retrospective annotated clinical specimens archived as formalin-fixed paraffin-embedded (FFPE) material. Mass spectrometry-based metabolomic analysis was performed in matched frozen and FFPE human prostate cancers as well as isogenic prostate cancer cell lines...
January 10, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28073170/loss-of-hsef-promotes-metastasis-through-up-regulation-of-emt-in-prostate-cancer
#8
S Hori, K Wadhwa, V Pisupati, V Zecchini, A Ramos-Montoya, A Y Warren, D E Neal, V J Gnanapragasam
We have previously reported that the negative regulator Similar Expression to FGF (hSef) is down-regulated in prostate cancer and its loss is associated with clinical metastasis. Here, we explored the mechanistic basis of this finding. We first confirmed our clinical observation by testing hSef manipulation in an in vivo metastasis model. hSef stable expressing cells (PC3M-hSef) or empty vector controls (PC3M-EV) were injected subcutaneously into the lateral thoracic walls of NOD-SCID gamma mice and lungs were harvested at autopsy...
January 10, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28072762/giving-axl-the-axe-targeting-axl-in-human-malignancy
#9
Carl M Gay, Kavitha Balaji, Lauren Averett Byers
The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunologic response. Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers...
January 10, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28068672/genomic-hallmarks-of-localized-non-indolent-prostate-cancer
#10
Michael Fraser, Veronica Y Sabelnykova, Takafumi N Yamaguchi, Lawrence E Heisler, Julie Livingstone, Vincent Huang, Yu-Jia Shiah, Fouad Yousif, Xihui Lin, Andre P Masella, Natalie S Fox, Michael Xie, Stephenie D Prokopec, Alejandro Berlin, Emilie Lalonde, Musaddeque Ahmed, Dominique Trudel, Xuemei Luo, Timothy A Beck, Alice Meng, Junyan Zhang, Alister D'Costa, Robert E Denroche, Haiying Kong, Shadrielle Melijah G Espiritu, Melvin L K Chua, Ada Wong, Taryne Chong, Michelle Sam, Jeremy Johns, Lee Timms, Nicholas B Buchner, Michèle Orain, Valérie Picard, Helène Hovington, Alexander Murison, Ken Kron, Nicholas J Harding, Christine P'ng, Kathleen E Houlahan, Kenneth C Chu, Bryan Lo, Francis Nguyen, Constance H Li, Ren X Sun, Richard de Borja, Christopher I Cooper, Julia F Hopkins, Shaylan K Govind, Clement Fung, Daryl Waggott, Jeffrey Green, Syed Haider, Michelle A Chan-Seng-Yue, Esther Jung, Zhiyuan Wang, Alain Bergeron, Alan Dal Pra, Louis Lacombe, Colin C Collins, Cenk Sahinalp, Mathieu Lupien, Neil E Fleshner, Housheng H He, Yves Fradet, Bernard Tetu, Theodorus van der Kwast, John D McPherson, Robert G Bristow, Paul C Boutros
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries...
January 19, 2017: Nature
https://www.readbyqxmd.com/read/28067370/automated-3d-printed-unibody-immunoarray-for-chemiluminescence-detection-of-cancer-biomarker-proteins
#11
C K Tang, A Vaze, J F Rusling
A low cost three-dimensional (3D) printed clear plastic microfluidic device was fabricated for fast, low cost automated protein detection. The unibody device features three reagent reservoirs, an efficient 3D network for passive mixing, and an optically transparent detection chamber housing a glass capture antibody array for measuring chemiluminescence output with a CCD camera. Sandwich type assays were built onto the glass arrays using a multi-labeled detection antibody-polyHRP (HRP = horseradish peroxidase)...
January 9, 2017: Lab on a Chip
https://www.readbyqxmd.com/read/28061542/an-efficient-method-for-native-protein-purification-in-the-selected-range-from-prostate-cancer-tissue-digests
#12
Rumana Ahmad, Carrie D Nicora, Anil K Shukla, Richard D Smith, Wei-Jun Qian, Alvin Y Liu
BACKGROUND: Prostate cancer (CP) cells differ from their normal counterpart in gene expression. Genes encoding secreted or extracellular proteins with increased expression in CP may serve as potential biomarkers. For their detection and quantification, assays based on monoclonal antibodies are best suited for development in the clinical setting. One approach to obtain antibodies is to use recombinant proteins as immunogen. However, the synthesis of recombinant protein for each identified candidate is time-consuming and expensive...
December 2016: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28061466/prostate-cancer-proteomics-current-trends-and-future-perspectives-for-biomarker-discovery
#13
Cristiana Pistol Tanase, Elena Codrici, Ionela Daniela Popescu, Simona Mihai, Ana-Maria Enciu, Laura Georgiana Necula, Adrian Preda, Gener Ismail, Radu Albulescu
The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment...
January 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28057891/prostate-cancer-pi3k-pten-and-prognosis
#14
REVIEW
Helen M Wise, Miguel A Hermida, Nicholas R Leslie
Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most common driving events in prostate cancer development. The observed mechanisms of PTEN loss are diverse, but both homozygous and heterozygous genomic deletions including PTEN are frequent, and often accompanied by loss of detectable protein as assessed by immunohistochemistry (IHC). The occurrence of PTEN loss is highest in aggressive metastatic disease and this has driven the development of PTEN as a prognostic biomarker, either alone or in combination with other factors, to distinguish indolent tumours from those likely to progress...
February 1, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/28057717/pathology-driven-comprehensive-proteomic-profiling-of-the-prostate-cancer-tumour-microenvironment
#15
Lisa Staunton, Claire Tonry, Rosina Lis, Virginia Espina, Lance Liotta, Rosanna Inziatari, Michaela Bowden, Aurelie Fabre, John O'Leary, Stephen P Finn, Massimo Loda, Stephen R Pennington
: Prostate cancer (PCa) is the second most common cancer in men worldwide. Gleason grading is an important predictor of PCa outcomes and is influential in determining patient treatment options. Clinical decisions based on a Gleason score of 7 are difficult as the prognosis for individuals diagnosed with Gleason 4+3 cancer is much worse than for those diagnosed with Gleason 3+4 cancer. Laser capture microdissection (LCM) is a highly precise method to isolate specific cell populations or discrete microregions from tissues...
January 5, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28056439/fe3o4-nanoparticles-on-graphene-oxide-sheets-for-isolation-and-ultrasensitive-amperometric-detection-of-cancer-biomarker-proteins
#16
Mohamed Sharafeldin, Gregory W Bishop, Snehasis Bhakta, Abdelhamid El-Sawy, Steven L Suib, James F Rusling
Ultrasensitive mediator-free electrochemical detection for biomarker proteins was achieved at low cost using a novel composite of Fe3O4 nanoparticles loaded onto graphene oxide (GO) nano-sheets (Fe3O4@GO). This paramagnetic Fe3O4@GO composite (1µm size range) was decorated with antibodies against prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA), and then used to first capture these biomarkers and then deliver them to an 8-sensor detection chamber of a microfluidic immunoarray. Screen-printed carbon sensors coated with electrochemically reduced graphene oxide (ERGO) and a second set of antibodies selectively capture the biomarker-laden Fe3O4@GO particles, which subsequently catalyze hydrogen peroxide reduction to detect PSA and PSMA...
December 27, 2016: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/28054319/exosomal-micrornas-in-liquid-biopsies-future-biomarkers-for-prostate-cancer
#17
REVIEW
A Valentino, P Reclusa, R Sirera, M Giallombardo, C Camps, P Pauwels, S Crispi, C Rolfo
Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level...
January 4, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28054089/separation-and-dual-detection-of-prostate-cancer-cells-and-protein-biomarkers-using-a-microchip-device
#18
Wanfeng Huang, Chun-Li Chang, Norman D Brault, Onur Gur, Zhe Wang, Shadia I Jalal, Philip S Low, Timothy L Ratliff, Roberto Pili, Cagri A Savran
Current efforts for the detection of prostate cancer using only prostate specific antigen are not ideal and indicate a need to develop new assays - using multiple targets - that can more accurately stratify disease states. We previously introduced a device capable of the concurrent detection of cellular and molecular markers from a single sample fluid. Here, an improved design, which achieves affinity as well as size-based separation of captured targets using antibody-conjugated magnetic beads and a silicon chip containing micro-apertures, is presented...
January 5, 2017: Lab on a Chip
https://www.readbyqxmd.com/read/28052017/rhcg-and-tcaf1-promoter-hypermethylation-predicts-biochemical-recurrence-in-prostate-cancer-patients-treated-by-radical-prostatectomy
#19
Siri H Strand, Michal Switnicki, Mia Moller, Christa Haldrup, Tine M Storebjerg, Jakob Hedegaard, Iver Nordentoft, Soren Hoyer, Michael Borre, Jakob S Pedersen, Peter J Wild, Jong Y Park, Torben F Orntoft, Karina D Sorensen
PURPOSE: The lack of biomarkers that can distinguish aggressive from indolent prostate cancer has caused substantial overtreatment of clinically insignificant disease. Here, by genome-wide DNA methylome profiling, we sought to identify new biomarkers to improve the accuracy of prostate cancer diagnosis and prognosis. EXPERIMENTAL DESIGN: Eight novel candidate markers, COL4A6, CYBA, TCAF1 (FAM115A), HLF, LINC01341 (LOC149134), LRRC4, PROM1, and RHCG, were selected from Illumina Infinium HumanMethylation450 BeadChip analysis of 21 tumor (T) and 21 non-malignant (NM) prostate specimens...
December 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/28049525/nutrition-therapy-with-high-intensity-interval-training-to-improve-prostate-cancer-related-fatigue-in-men-on-androgen-deprivation-therapy-a-study-protocol
#20
Brenton J Baguley, Tina L Skinner, Michael D Leveritt, Olivia R L Wright
BACKGROUND: Cancer-related fatigue is one of the most prevalent, prolonged and distressing side effects of prostate cancer treatment with androgen deprivation therapy. Preliminary evidence suggests natural therapies such as nutrition therapy and structured exercise prescription can reduce symptoms of cancer-related fatigue. Men appear to change their habitual dietary patterns after prostate cancer diagnosis, yet prostate-specific dietary guidelines provide limited support for managing adverse side effects of treatment...
January 3, 2017: BMC Cancer
keyword
keyword
101574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"